Central Nervous System Biomarkers Market by Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease Indication (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease), Application, End-User - Global Forecast 2024-2030

Central Nervous System Biomarkers Market by Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease Indication (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease), Application, End-User - Global Forecast 2024-2030


The Central Nervous System Biomarkers Market size was estimated at USD 4.37 billion in 2023 and expected to reach USD 4.81 billion in 2024, at a CAGR 10.39% to reach USD 8.73 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Central Nervous System Biomarkers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Central Nervous System Biomarkers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abbvie PLC, Acumen Pharmaceuticals Inc., Agilent Technologies, Inc., Aposense Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc, BioMérieux SA, Bruker Corporation, C2N Diagnostics, LLC, Cerevance, LLC, Charles River Laboratories International, Inc., Eli Lilly and Co., F. Hoffmann-La Roche AG, Geno Technology Inc., Invicro LLC, Laboratory Corporation of America Holdings, Merck KGaA, Myriad Genetics, Inc., Novartis AG, Qiagen N.V., Quanterix Corporation, Siemens Healthcare GmbH, SynapCell, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage


This research report categorizes the Central Nervous System Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Efficacy Biomarkers
Safety Biomarkers
Validation Biomarkers
Disease Indication
Alzheimer’s Disease
Multiple Sclerosis
Parkinson’s Disease
Traumatic Brain Injury
Application
Diagnostics
Disease Risk Assessment
Drug Discovery & Development
Personalized Medicines
End-User
Clinics & Hospitals
Diagnostic Labs
Research Centers
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Central Nervous System Biomarkers Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Central Nervous System Biomarkers Market?
3. What are the technology trends and regulatory frameworks in the Central Nervous System Biomarkers Market?
4. What is the market share of the leading vendors in the Central Nervous System Biomarkers Market?
5. Which modes and strategic moves are suitable for entering the Central Nervous System Biomarkers Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Central Nervous System Biomarkers Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in obesity leading to neurological illnesses
5.1.1.2. Availability of central nervous system biomarkers for clinical use
5.1.1.3. Development of genomics, proteomics, and imaging systems
5.1.2. Restraints
5.1.2.1. High validation cost and unfavorable reimbursement costs
5.1.3. Opportunities
5.1.3.1. Improving research and development activities for central nervous system biomarkers
5.1.3.2. Emerging focus on building strategic alliances and introduction of new products and technology
5.1.4. Challenges
5.1.4.1. Lack of skilled technical professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Central Nervous System Biomarkers Market, by Type
6.1. Introduction
6.2. Efficacy Biomarkers
6.3. Safety Biomarkers
6.4. Validation Biomarkers
7. Central Nervous System Biomarkers Market, by Disease Indication
7.1. Introduction
7.2. Alzheimer’s Disease
7.3. Multiple Sclerosis
7.4. Parkinson’s Disease
7.5. Traumatic Brain Injury
8. Central Nervous System Biomarkers Market, by Application
8.1. Introduction
8.2. Diagnostics
8.3. Disease Risk Assessment
8.4. Drug Discovery & Development
8.5. Personalized Medicines
9. Central Nervous System Biomarkers Market, by End-User
9.1. Introduction
9.2. Clinics & Hospitals
9.3. Diagnostic Labs
9.4. Research Centers
10. Americas Central Nervous System Biomarkers Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Central Nervous System Biomarkers Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Central Nervous System Biomarkers Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Abbvie PLC
14.1.3. Acumen Pharmaceuticals Inc.
14.1.4. Agilent Technologies, Inc.
14.1.5. Aposense Ltd.
14.1.6. Becton, Dickinson and Company
14.1.7. Bio-Rad Laboratories, Inc
14.1.8. BioMérieux SA
14.1.9. Bruker Corporation
14.1.10. C2N Diagnostics, LLC
14.1.11. Cerevance, LLC
14.1.12. Charles River Laboratories International, Inc.
14.1.13. Eli Lilly and Co.
14.1.14. F. Hoffmann-La Roche AG
14.1.15. Geno Technology Inc.
14.1.16. Invicro LLC
14.1.17. Laboratory Corporation of America Holdings
14.1.18. Merck KGaA
14.1.19. Myriad Genetics, Inc.
14.1.20. Novartis AG
14.1.21. Qiagen N.V.
14.1.22. Quanterix Corporation
14.1.23. Siemens Healthcare GmbH
14.1.24. SynapCell
14.1.25. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 2. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2023 VS 2030
FIGURE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET DYNAMICS
FIGURE 7. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 10. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings